Samuel Trammell will Present his Research December 12, 2013
NAD+ METABOLOMICS AND ITS APPLICATION TO NICOTINAMIDE RIBOSIDE THERAPIES IN RODENTS
To support experiments that range from in vitro biochemistry to yeast, vertebrate cell culture, mouse, rat and human trials, we have improved upon our earlier LC-MS/MS assay of the NAD+ metabolome (1). The new assay utilizes separations on porous graphitic carbon and two sets of internal standards to overcome ion suppression effects plaguing external calibration based quantitation methods (2). This presentation will review newly optimized methods for separation and quantification of closely related analytes. Moreover, we will present evidence that the novel NAD+ precursor nicotinamide riboside supplementation prevents diabetic neuropathy in a Type 1 diabetic rat model.